Program
obeldesivir
Also written as “Obeldesivir”.
Its studies are mostly in COVID-19 · Respiratory Syncytial Virus Infections, led by Gilead Sciences.
Furthest: phase 3, since Oct 31, 20226 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 60 open or running | phase 3since Oct 31, 2022 | Oct 31, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2022First study: phase 3 study in COVID-19First studyNCT05603143 · 468 enrolled · Brazil, Bulgaria, Canada and more
- Feb 3, 2023Phase 3 study in COVID-19NCT05715528 · 2,011 enrolled · United States, Japan
- Aug 14, 2023Phase 3 study in COVID-19NCT05996744 · 3 enrolled · United States
- Sep 3, 2024Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06585150 · 150 enrolled · United States
- Nov 7, 2024Phase 2 study in Filovirus DiseaseNCT06682234
- Jan 15, 2025Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06784973 · 4 enrolled · United States, Japan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06784973Respiratory Syncytial Virus Infections · United States, Japan | 2 | Terminated | Apr 16, 2025 | 4 |
| NCT06682234Filovirus Disease | 2 | Withdrawn | Dec 2025 | 0 |
| NCT06585150Respiratory Syncytial Virus Infections · United States | 2 | Terminated | May 8, 2025 | 150 |
| NCT05996744COVID-19 · United States | 3 | Terminated | Feb 23, 2024 | 3 |
| NCT05715528COVID-19 · United States, Japan | 3 | Completed | Nov 28, 2023 | 2,011 |
| NCT05603143COVID-19 · Brazil, Bulgaria, Canada and more | 3 | Terminated | Nov 7, 2023 | 468 |
How it is read
Names in the registry
- “Obeldesivir”, 5 entries
- “obeldesivir”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 3 studies
- Respiratory Syncytial Virus Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.